Susquehanna Fundamental Investments’s AbbVie ABBV Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-18,259	Closed	-$2.72M	–	68
2023 Q3	$2.72M	Hold	18,259	–	–	0.18%	125
2023 Q2	$2.46M	Sell	18,259 -51,269	-74%	-$7.52M	0.09%	222
2023 Q1	$11.1M	Sell	69,528 -27,948	-29%	-$4.27M	0.26%	115
2022 Q4	$15.8M	Buy	97,476 +27,948	+40%	+$4.29M	0.27%	104
2022 Q3	$9.33M	Buy	+69,528	New	+$9.98M	0.16%	180
2020 Q2	–	Sell	-52,549	Closed	-$4M	–	960
2020 Q1	$4M	Buy	52,549 +26,299	+100%	+$2.24M	0.8%	41
2019 Q4	$2.32M	Sell	26,250 -4,100	-14%	-$340K	0.3%	108
2019 Q3	$2.3M	Sell	30,350 -44,750	-60%	-$3.07M	0.28%	117
2019 Q2	$5.46M	Buy	75,100 +800	+1%	+$62.9K	0.64%	46
2019 Q1	$5.99M	Buy	+74,300	New	+$6.08M	0.68%	44
2018 Q4	–	Sell	-12,500	Closed	-$1.18M	–	308
2018 Q3	$1.18M	Sell	12,500 -29,600	-70%	-$2.81M	0.2%	151
2018 Q2	$3.9M	Sell	42,100 -3,500	-8%	-$342K	0.58%	50
2018 Q1	$4.32M	Buy	+45,600	New	+$5.01M	0.51%	51

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Susquehanna Fundamental Investments's ABBV Position: Q4 2023 in Review

Susquehanna Fundamental Investments sold out of AbbVie (ABBV) in Q4 2023, closing a stake of 18,259 shares — an estimated $2.72M sold.

Susquehanna Fundamental Investments first reported a position in ABBV in Q1 2018 and held it in 13 quarters. The position peaked at $15.8M in Q4 2022. 3,323 funds tracked by Wall St. Rank hold ABBV as of Q4 2023.

Susquehanna Fundamental Investments reported no remaining AbbVie position as of Q4 2023 after selling out during the quarter.
Susquehanna Fundamental Investments sold 18,259 AbbVie shares in Q4 2023, an estimated $2.72M.
Susquehanna Fundamental Investments first reported a position in AbbVie in Q1 2018 and held it in 13 quarters.
Susquehanna Fundamental Investments's AbbVie position peaked at $15.8M in Q4 2022.
3,323 funds tracked by Wall St. Rank held AbbVie as of Q4 2023.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2023, filed 14 Feb 2024.